Low-dose aspirin promotes osteogenic differentiation and osteogenic activity in osteoporotic rats by regulating Opg/Rankl/Rank Axis
Purpose: To investigate the effect of low-dose aspirin (ASP) on osteogenic differentiation and osteogenic effects in osteoporotic rats, and the associated mechanism.
Methods: The bone marrow mesenchymal stem cells were randomly divided into 4 groups: control group and 3 drug groups treated with graded doses of ASP i.e. 0.5, 1 and 2 mmol/L, with 4 wells in each group. The OPG, RANKL protein expression levels, OPG/RANKL ratio, alkaline phosphatase (ALP) level, and ALP secretion at days 3, 5 and 7 were compared amongst the groups.
Results: ALP secretion in BMSCs was markedly higher in the 1 mmol/L ASP group than in control (p < 0.05). The OPG protein concentration and OPG/RANKL ratio were markedly higher in ASP-treated BMSCs than in control, while RANKL protein expression level was significantly lower than that in control (p < 0.05). In BMSCs treated with ASP at doses of 0.5 and 2 mmol/L, OPG protein expression levels and ratio of OPG/RANKL were markedly lower than those in 1 mmol/L ASP group, while the mean level of RANKL protein expression was markedly higher than that in 1 mmol/L ASP group (p < 0.05).
Conclusion: Low-dose aspirin increases the expression of ALP, and promotes calcification which relates to upregulation of OPG and inhibition of the OPG/RANKL/RANK axis. This provides new leads for the development of new anti-osteoporosis drugs.
Keywords: Aspirin, OPG, RANKL, RANK, Osteoporosis
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.